The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm

The disease burden of hepatitis C virus (HCV) is expected to increase as the infected population ages. A modelling approach was used to estimate the total number of viremic infections, diagnosed, treated and new infections in 2013. In addition, the model was used to estimate the change in the total number of HCV infections, the disease progression and mortality in 2013–2030. Finally, expert panel consensus was used to capture current treatment practices in each country. Using today's treatment paradigm, the total number of HCV infections is projected to decline or remain flat in all countries studied. However, in the same time period, the number of individuals with late‐stage liver disease is projected to increase. This study concluded that the current treatment rate and efficacy are not sufficient to manage the disease burden of HCV. Thus, alternative strategies are required to keep the number of HCV individuals with advanced liver disease and liver‐related deaths from increasing.

G. Esmat | E. Gower | M. Buti | R. Marinho | T. Berg | M. Sherman | F. Roudot-thoraval | F. Negro | L. Roberts | Ding‐Shinn Chen | J. Kao | T. Su | J. Fung | D. Semela | H. Razavi | T. R. D. Wit | G. Shiha | S. Tan | S. Tsang | R. Mohamed | G. Dore | J. Layden | A. Duberg | K. Kaita | R. Stauber | D. Lavanchy | C. Sarrazin | W. Laleman | G. Ergör | M. Bilodeau | U. Akarca | S. Mauss | H. Wedemeyer | I. Waked | J. Calleja | G. Esmat | W. Doss | W. Rosenberg | J. Parkes | W. Vogel | A. Zekry | P. Marotta | K. Peltekian | B. Müllhaupt | R. Chien | J. Wiegand | R. Phillips | H. Vlierberghe | H. Krarup | R. Njouom | O. Opare-Sem | A. Vince | C. Hézode | S. Roberts | R. Myers | P. Stärkel | H. Al-Romaihi | N. Örmeci | F. Bihl | M. Cornberg | Z. Ghandour | M. Gschwantler | D. Vandijck | P. Bruggmann | K. Falconer | M. Krajden | H. Wedemeyer | J. Gerstoft | P. Marotta | W. Vogel | H. Razavi | I. Waked | C. Sarrazin | R. P. Myers | R. Idilman | F. Calinas | M. C. Mendes Correa | C. Hézode | P. Lázaro | U. Akarca | S. Aleman | İ. Balık | T. Berg | F. Bihl | M. Bilodeau | A. J. Blasco | C. E. Brandão Mello | P. Bruggmann | M. Buti | J. L. Calleja | H. Cheinquer | P. B. Christensen | M. Clausen | H. S. M. Coelho | M. E. Cramp | G. J. Dore | W. Doss | A. S. Duberg | M. H. El‐Sayed | G. Ergör | K. Falconer | J. Félix | M. L. G. Ferraz | P. R. Ferreira | S. Frankova | J. García‐Samaniego | J. A. Giria | F. L. Gonçales | M. Gschwantler | M. Guimarães Pessôa | S. J. Hindman | H. Hofer | P. Husa | M. Kåberg | K. D. E. Kaita | A. Kautz | S. Kaymakoglu | M. Krajden | H. Krarup | W. Laleman | D. Lavanchy | R. T. Marinho | S. Mauss | C. Moreno | K. Murphy | F. Negro | V. Nemecek | N. Örmeci | A. L. H. Øvrehus | J. Parkes | K. Pasini | K. M. Peltekian | A. Ramji | N. Reis | S. K. Roberts | W. M. Rosenberg | F. Roudot‐Thoraval | S. D. Ryder | R. Sarmento‐Castro | D. Semela | M. Sherman | G. E. Shiha | W. Sievert | J. Sperl | P. Stärkel | R. E. Stauber | A. J. Thompson | P. Urbanek | P. Damme | I. Thiel | H. Vlierberghe | D. Vandijck | N. Weis | J. Wiegand | A. Yosry | A. Zekry | M. Cornberg | B. Müllhaupt | C. Estes | A. Nersesov | J. Gerstoft | P. Damme | C. Loo | W. Sievert | S. Ryder | P. Lázaro | P. Ondoa | A. Bane | S. Kaymakoğlu | I. Kotzev | K. Tchernev | A. Yosry | A. Ramji | Said A. Al-Busafi | J. García-Samaniego | C. Estes | J. Félix | M. El-Sayed | W. Chuang | I. Gamkrelidze | E. Ngige | P. Christensen | N. Weis | A. Thompson | H. Coelho | H. Hofer | M. Clausen | F. Arome | J. Khamis | F. Gonçales | S. Aleman | M. L. Ferraz | W. Lao | H. Cheinquer | M. Cramp | K. Razavi-Shearer | R. Jahis | M. Morović | S. Frankova | J. Sperl | P. Husa | A. Blasco | Y. Kamel | S. Oguche | I. Hrstic | Manik Sharma | S. Blach | M. Kåberg | K. Antonov | D. Jelev | R. Sarmento-Castro | O. Akin | J. Genov | O. Lesi | D. Nonković | B. Lukšić | S. Robbins | A. Kautz | W. Hamoudi | O. Njoya | C. Tzeuton | S. Himatt | M. Derbala | E. Gower | C. Anyaike | M. Youbi | Y. Hui | K. Naamani | A. Maaroufi | V. W. Wong | D. Adda | B. Gómez | Michael K. K. Li | J. Schmelzer | K. Yesmembetov | W. Ampofo | R. Mitova | C. Moreno | M. Lai | A. Workneh | A. Malu | C. J. Chen | M. C. Mendes Correa | A. John | K. Sultan | M. T. Butt | H. Chan | P. Urbánek | K. Kaliaskarova | A. Øvrehus | R. Idilman | Mei-Hsuan Lee | T. Reic | V. Němeček | L. Mateva | M. Abdelmageed | S. Brandon | B. Bright | D. Cuellar | A. A. Elbardiny | E. Farag | M. Ghuloom | J. Gunter | J. Habeeb | O. Hajelssedig | C. Huang | H. Khattabi | I. Khoudri | A. Konysbekova | K. Murphy | H. Nde | D. Nonković | S. Obekpa | E. Okolo | O. Omede | C. Omuemu | Y. Prokopenko | B. Redae | S. Ugoeze | R. Vi | H. Wani | R. Yacoub | İ. Balık | C. E. Brandão Mello | F. Calinas | P. Ferreira | J. Gíria | M. Guimarães Pessôa | S. Hindman | N. Reis | I. Thiel | S. Kaabi | O. Tsang | C. C. Hu | N. Dweik | Pei‐Jer Chen | M. Borodo | K. Pasini | S. Owusu-Ofori | B. Uzochukwu | A. Lo | K. A. Ejji | I. Ghazzawi | Maheeba Abdulla | S. Fraňková | M. Simonova | Man-Fung Yuen | C. Ríos | S. J. Sanad | V. García | J. A. Salman | D. Razavi‐Shearer | J. A. Qamish | I. Cárdenas | A. A. Baqali | M. A. Sadadi | M. AlBadri | B. Mustapha

[1]  J. Marrugat,et al.  Prevalencia de las hepatitis B y C en diversas comarcas de Cataluña: estudio transversal , 2002 .

[2]  L. Chyczewskî,et al.  Known and probable risk factors for hepatitis C infection: a case series in north-eastern Poland. , 2006, World journal of gastroenterology.

[3]  R. Sertöz,et al.  Possible transmission risks and genotype distribution of hepatitis C virus infection in Western Turkey. , 2013, The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology.

[4]  J. Tanaka,et al.  Sex- and Age-Specific Carriers of Hepatitis B and C Viruses in Japan Estimated by the Prevalence in the 3,485,648 First-Time Blood Donors during 1995–2000 , 2004, Intervirology.

[5]  L. Abu-Raddad,et al.  Evidence of intense ongoing endemic transmission of hepatitis C virus in Egypt , 2010, Proceedings of the National Academy of Sciences.

[6]  M. Choti,et al.  Differences in characteristics of patients with and without known risk factors for hepatocellular carcinoma in the United States. , 2007, World journal of gastroenterology.

[7]  M. Davoli,et al.  Drug-related mortality and its impact on adult mortality in eight European countries. , 2006, European journal of public health.

[8]  Myrna M. Khan,et al.  A retrospective cohort study: 10-year trend of disease-modifying antirheumatic drugs and biological agents use in patients with rheumatoid arthritis at Veteran Affairs Medical Centers , 2013, BMJ Open.

[9]  Z. Goodman,et al.  Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis c. , 2001, Journal of hepatology.

[10]  R. W. Mccollum.  The natural history of hepatitis. , 1969, Bulletin of the New York Academy of Medicine.

[11]  N. Tabibian.  Hepatocellular carcinoma in the United States. , 1988, American family physician.

[12]  C. Taylor,et al.  Death and survival in a cohort of heroin addicts from London clinics: a 22-year follow-up study. , 1994, Addiction.

[13]  T. Berg,et al.  Evaluation of liver disease progression in the German hepatitis C virus (1b)‐contaminated anti‐D cohort at 35 years after infection , 2014, Hepatology.

[14]  Richard Gray,et al.  HIV, viral hepatitis and sexually transmissible infections in Australia , 2016 .

[15]  D. Struck,et al.  Hepatitis C virus genotypes distribution and transmission risk factors in Luxembourg from 1991 to 2006. , 2008, World journal of gastroenterology.

[16]  Louisa Degenhardt,et al.  Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews , 2011, The Lancet.

[17]  A. Luke,et al.  High frequency of active HCV infection among seropositive cases in west Africa and evidence for multiple transmission pathways. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[18]  O. Reichard,et al.  Cost-effectiveness of peginterferon alfa-2b in combination with ribavirin as initial treatment for chronic hepatitis C in Sweden , 2006, Scandinavian journal of infectious diseases.

[19]  M. Turchi,et al.  Prevalence and risk factors of Hepatitis C virus infection in Brazil, 2005 through 2009: a cross-sectional study , 2013, BMC Infectious Diseases.

[20]  M. El-Hazmi,et al.  Profile of hepatitis C virus and the possible modes of transmission of the virus in the Gizan area of Saudi Arabia: a community-based study. , 1995, Annals of tropical medicine and parasitology.

[21]  M. Daw,et al.  Geographic distribution of HCV genotypes in Libya and analysis of risk factors involved in their transmission , 2015, BMC Research Notes.

[22]  G. Dusheiko,et al.  Natural history of hepatitis C. , 2014, Journal of hepatology.

[23]  A. Hatzakis,et al.  Future trends of HCV‐related cirrhosis and hepatocellular carcinoma under the currently available treatments , 2005 .

[24]  S. Hamid,et al.  Health care risk factors among women and personal behaviours among men explain the high prevalence of hepatitis C virus infection in Karachi, Pakistan , 2010, Journal of viral hepatitis.

[25]  F. Berr,et al.  Low frequency of cirrhosis in a hepatitis C (genotype 1b) single‐source outbreak in germany: A 20‐year multicenter study , 2000, Hepatology.

[26]  M. Salminen,et al.  European monitoring of notifications of hepatitis C virus infection in the general population and among injecting drug users (IDUs) - the need to improve quality and comparability. , 2008, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[27]  A. Burguete-García,et al.  Hepatitis C seroprevalence and correlation between viral load and viral genotype among primary care clients in Mexico. , 2011, Salud publica de Mexico.

[28]  J. Ward,et al.  Hepatocellular carcinoma - United States, 2001-2006. , 2010, MMWR. Morbidity and mortality weekly report.

[29]  T. Rhodes,et al.  Global estimates of prevalence of HCV infection among injecting drug users. , 2007, The International journal on drug policy.

[30]  A. Labbé,et al.  Noble goals, unforeseen consequences: control of tropical diseases in colonial Central Africa and the iatrogenic transmission of blood‐borne viruses , 2008, Tropical medicine & international health : TM & IH.

[31]  H. Lee,et al.  Clinical and epidemiological features of hepatitis C virus infection in South Korea: A prospective, multicenter cohort study , 2013, Journal of medical virology.

[32]  C. Dolea,et al.  World Health Organization , 1949, International Organization.

[33]  A. Blaxhult,et al.  Cause of death in individuals with chronic HBV and/or HCV infection, a nationwide community‐based register study , 2008, Journal of viral hepatitis.

[34]  G. Dore,et al.  Hospitalization rates associated with hepatitis B and HIV co-infection, age and sex in a population-based cohort of people diagnosed with hepatitis C , 2010, Epidemiology and Infection.

[35]  G. Touloumi,et al.  Significant epidemiological changes in chronic hepatitis C infection: results of the nationwide HEPNET-GREECE cohort study. , 2011, Hippokratia.

[36]  J. Desenclos,et al.  Prevalence of hepatitis B and hepatitis C virus infections in France in 2004: Social factors are important predictors after adjusting for known risk factors , 2010, Journal of medical virology.

[37]  J. Connell,et al.  Determination of the burden of hepatitis C virus infection in Ireland , 2011, Epidemiology and Infection.

[38]  M A Gerber,et al.  The natural history of community-acquired hepatitis C in the United States. The Sentinel Counties Chronic non-A, non-B Hepatitis Study Team. , 1992, The New England journal of medicine.

[39]  W KOUWENAAR,et al.  [The National Institute of Public Health]. , 1952, Nederlands tijdschrift voor geneeskunde.

[40]  Bernadette A. Thomas,et al.  Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010 , 2012, The Lancet.

[41]  C. Latkin,et al.  Liquid Drugs and High Dead Space Syringes May Keep HIV and HCV Prevalence High – A Comparison of Hungary and Lithuania , 2010, European Addiction Research.

[42]  M. Farrell,et al.  Drug-related mortality and fatal overdose risk: Pilot cohort study of heroin users recruited from specialist drug treatment sites in London , 2003, Journal of Urban Health.

[43]  A. Blaxhult,et al.  The epidemiology of hepatitis C virus infection in Sweden. , 2008, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[44]  J. Desenclos,et al.  Impact of hepatitis C triple therapy availability upon the number of patients to be treated and associated costs in France: a model-based analysis , 2011, Gut.

[45]  M. Buti,et al.  Predicted effects of treatment for HCV infection vary among European countries. , 2012, Gastroenterology.

[46]  R. Stohler,et al.  Combined effects of law enforcement and substitution treatment on heroin mortality. , 2010, Drug and alcohol review.

[47]  T. Katzenstein,et al.  Incidence and characteristics of sexually transmitted acute hepatitis C virus infection among HIV-positive men who have sex with men in Copenhagen, Denmark during four years (2006–2009): A retrospective cohort study , 2011, Scandinavian journal of infectious diseases.

[48]  Chien-Jen Chen,et al.  Hepatitis C virus infection in an area hyperendemic for hepatitis B and chronic liver disease: the Taiwan experience. , 1990, The Journal of infectious diseases.

[49]  P. Michielsen,et al.  A pilot observational survey of hepatitis C in Belgium. , 2008, Acta gastro-enterologica Belgica.

[50]  Reza Assadi,et al.  The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013 , 2016, The Lancet.

[51]  Chien-Jen Chen,et al.  Transmission of hepatitis C virus in Taiwan: Prevalence and risk factors based on a nationwide survey , 1999, Journal of medical virology.

[52]  Z. Younossi,et al.  Cost effectiveness of interferon α2b combined with ribavirin for the treatment of chronic hepatitis C , 1999, Hepatology.

[53]  H. J. Vriend,et al.  Hepatitis C virus prevalence in The Netherlands: migrants account for most infections , 2012, Epidemiology and Infection.

[54]  P. Kristian,et al.  [Epidemiological survey of hepatitis C at the Clinic of Infectology and Travel Medicine in Kosice]. , 2009, Epidemiologie, mikrobiologie, imunologie : casopis Spolecnosti pro epidemiologii a mikrobiologii Ceske lekarske spolecnosti J.E. Purkyne.

[55]  H. Razavi,et al.  Global epidemiology and genotype distribution of the hepatitis C virus infection. , 2014, Journal of hepatology.

[56]  F. Al-Faleh.  Hepatitis C virus infection: an update. , 1995, Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia.

[57]  R. Grant,et al.  Barriers to the treatment of hepatitis C. Patient, provider, and system factors. , 2005, Journal of general internal medicine.

[58]  J. Sunyer,et al.  [Prevalence of hepatitis B and hepatitis C viruses in different counties of Catalonia, Spain: cross-sectional study]. , 2002, Medicina clinica.

[59]  M. Zwahlen,et al.  Cohort Profile: the Swiss Hepatitis C Cohort Study (SCCS). , 2007, International journal of epidemiology.

[60]  G. Lachenal,et al.  The hepatitis C virus epidemic in Cameroon: genetic evidence for rapid transmission between 1920 and 1960. , 2007, Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases.

[61]  A. Rivas-Estilla,et al.  Genotyping of hepatitis C virus (HCV) in infected patients from Northeast Mexico. , 2008, Annals of hepatology.

[62]  A. de Gottardi,et al.  Hepatitis B and C in Switzerland - healthcare provider initiated testing for chronic hepatitis B and C infection. , 2013, Swiss medical weekly.

[63]  G. Dore,et al.  Estimation of stage‐specific fibrosis progression rates in chronic hepatitis C virus infection: A meta‐analysis and meta‐regression , 2008, Hepatology.

[64]  Steve Bhimji,et al.  Transplantation, Organ Procurement and Transplantation Network (OPTN) , 2015 .

[65]  H. El‐Serag,et al.  Epidemiology of viral hepatitis and hepatocellular carcinoma. , 2012, Gastroenterology.

[66]  M. Buti,et al.  Strategies to manage hepatitis C virus (HCV) disease burden , 2014, Journal of viral hepatitis.

[67]  T. Gojobori,et al.  A comparison of the molecular clock of hepatitis C virus in the United States and Japan predicts that hepatocellular carcinoma incidence in the United States will increase over the next two decades , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[68]  R. Breban,et al.  Towards realistic estimates of HCV incidence in Egypt , 2013, Journal of viral hepatitis.

[69]  H. Razavi,et al.  Chronic Hepatitis C Virus (HCV) Disease Burden and Cost in the United States , 2013, Hepatology.

[70]  O. Weiland,et al.  A risk for hepatocellular carcinoma persists long-term after sustained virologic response in patients with hepatitis C-associated liver cirrhosis. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[71]  O. Yokosuka,et al.  Lower incidence of hepatic failure than hepatocellular carcinoma in Japanese patients with chronic Hepatitis C , 2005, Liver international : official journal of the International Association for the Study of the Liver.

[72]  M. Gouya,et al.  Prevalence and correlates of hepatitis C virus infection among injecting drug users in Tehran. , 2007, The International journal on drug policy.

[73]  M. M. Ennaji,et al.  Prevalence and risk factors of hepatitis B and C virus infections among the general population and blood donors in Morocco , 2013, BMC Public Health.

[74]  J B Wong,et al.  Estimates of the Cost-Effectiveness of a Single Course of Interferon-2b in Patients with Histologically Mild Chronic Hepatitis C , 1997, Annals of Internal Medicine.

[75]  B. Šarkanj,et al.  Most common HCV genotypes in patients from north-eastern Croatia. , 2014, Acta medica academica.

[76]  J. L. Thomsen,et al.  Surveillance of HIV and Viral Hepatitis by Analysis of Samples from Drug Related Deaths , 2006, European Journal of Epidemiology.

[77]  A. Widell,et al.  Hepatitis C in Lithuania: incidence, prevalence, risk factors and viral genotypes. , 1995, Clinical and diagnostic virology.

[78]  G. Schwarzer,et al.  Seroprevalence of Chronic Hepatitis B Virus Infection and Prior Immunity in Immigrants and Refugees: A Systematic Review and Meta-Analysis , 2012, PloS one.

[79]  A. Valleron,et al.  Quantification of fibrosis progression in patients with chronic hepatitis C using a Markov model , 2002, Journal of viral hepatitis.

[80]  H. Krarup,et al.  Mortality in HIV‐infected injection drug users with active vs cleared hepatitis C virus‐infection: a population‐based cohort study , 2010, Journal of viral hepatitis.

[81]  L. Seeff,et al.  Natural history of hepatitis C , 1997, Hepatology.

[82]  R. Malekzadeh,et al.  Strategies to manage hepatitis C virus infection disease burden – volume 3 , 2015, Journal of viral hepatitis.

[83]  S. Sekiguchi,et al.  The epidemiology and infection route of asymptomatic HCV carriers detected through blood donations , 1993, Gastroenterologia Japonica.

[84]  M. Daw,et al.  Prevalence of hepatitis B and hepatitis C infection in Libya: results from a national population based survey , 2014, BMC Infectious Diseases.

[85]  O. Ekeberg,et al.  A 20-year prospective study of mortality and causes of death among hospitalized opioid addicts in Oslo , 2008, BMC psychiatry.

[86]  R. Solà,et al.  Prevalence of hepatitis B and hepatitis C viruses in different counties of Catalonia, Spain: cross-sectional study: cross-sectional study , 2002 .

[87]  A. Gómez,et al.  La inyección de drogas en Bogotá: una amenaza creciente , 2005 .

[88]  S. Friedman,et al.  Reversal, maintenance or progression: what happens to the liver after a virologic cure of hepatitis C? , 2014, Antiviral research.

[89]  A. Blaxhult,et al.  The burden of hepatitis C in Sweden: a national study of inpatient care , 2011, Journal of viral hepatitis.

[90]  A. Hatzakis,et al.  Reconstructing and predicting the hepatitis C virus epidemic in Greece: increasing trends of cirrhosis and hepatocellular carcinoma despite the decline in incidence of HCV infection , 2004, Journal of viral hepatitis.

[91]  M. Buti,et al.  A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel , 2011, Liver international : official journal of the International Association for the Study of the Liver.

[92]  M. Rahman,et al.  Mortality and survival among a cohort of drug injectors in Glasgow, 1982-1994. , 1997, Addiction.

[93]  McCollum Rw.  The natural history of hepatitis. , 1969 .

[94]  K. Kotoh,et al.  Hepatocarcinogenesis in chronic hepatitis C patients achieving a sustained virological response to interferon: significance of lifelong periodic cancer screening for improving outcomes , 2014, Journal of Gastroenterology.

[95]  M. Melbye,et al.  Survival after blood transfusion , 2008, Transfusion.

[96]  M. Russo,et al.  High Deferral Rates and Poorer Treatment Outcomes for HCV Patients with Psychiatric and Substance Use Comorbidities , 2007, Digestive Diseases and Sciences.

[97]  V. Wong,et al.  Targeted hepatitis C screening among ex‐injection drug users in the community , 2014, Journal of gastroenterology and hepatology.

[98]  B. Schlosser,et al.  High Prevalence of Anti-HCV Antibodies in Two Metropolitan Emergency Departments in Germany: A Prospective Screening Analysis of 28,809 Patients , 2012, PloS one.

[99]  A. Mitwalli,et al.  Hepatitis C virus seroprevalence rate among Saudis. , 2003, Saudi medical journal.

[100]  M. Buti,et al.  Historical epidemiology of hepatitis C virus (HCV) in selected countries , 2014, Journal of viral hepatitis.

[101]  Eva Negri,et al.  Worldwide mortality from cirrhosis: an update to 2002. , 2007, Journal of hepatology.

[102]  J. Kaldor,et al.  The epidemiology of hepatitis C in Australia: Notifications, treatment uptake and liver transplantations, 1997–2006 , 2009, Journal of gastroenterology and hepatology.

[103]  E. Croes,et al.  The Netherlands drug situation 2009 : report to the EMCDDA by the Reitox National Focal Point , 2010 .

[104]  L. Gheorghe,et al.  The prevalence and risk factors of hepatitis C virus infection in adult population in Romania: a nationwide survey 2006 - 2008. , 2010, Journal of gastrointestinal and liver diseases : JGLD.

[105]  M. Poljak,et al.  Hepatitis C virus genotypes in 1,504 patients in Slovenia, 1993–2007 , 2009, Journal of medical virology.

[106]  M. Maticic.  A national multidisciplinary healthcare network for treatment of hepatitis C in people who inject drugs in Slovenia , 2014, BMC Infectious Diseases.

[107]  P. Allebeck,et al.  Mortality in patients with substance abuse: a follow-up in Stockholm County, 1973-1984. , 1991, The International journal of the addictions.

[108]  E. Ridruejo,et al.  Efficacy, tolerability and safety in the treatment of chronic hepatitis C with combination of PEG-Interferon - Ribavirin in daily practice. , 2010, Annals of hepatology.

[109]  V. Hope,et al.  Prevalence and estimation of hepatitis B and C infections in the WHO European Region: a review of data focusing on the countries outside the European Union and the European Free Trade Association , 2013, Epidemiology and Infection.

[110]  Dmitri A. Jdanov,et al.  Human Mortality Database , 2019, Encyclopedia of Gerontology and Population Aging.

[111]  J B Wong,et al.  Estimating the future health burden of chronic hepatitis C and human immunodeficiency virus infections in the United States , 2007, Journal of viral hepatitis.

[112]  J. Guàrdia,et al.  Epidemiological and clinical aspects of hepatitis C virus infection in the Russian Republic of Daghestan , 1998, European Journal of Epidemiology.

[113]  X. Forns,et al.  Hospital admission is a relevant source of hepatitis C virus acquisition in Spain. , 2008, Journal of hepatology.

[114]  R. Marinho,et al.  EPIDEMIOLOGICAL ASPECTS OF HEPATITIS C IN PORTUGAL , 2001, Journal of gastroenterology and hepatology.

[115]  Y. Hutin,et al.  The global burden of viral hepatitis: better estimates to guide hepatitis elimination efforts , 2016, The Lancet.

[116]  W. Tsoi,et al.  Risk factor analysis of hepatitis C virus infection among Chinese blood donors in Hong Kong , 2012, Transfusion medicine.

[117]  M. Abdel-hamid,et al.  Association of HCV with diabetes mellitus: an Egyptian case-control study , 2011, Virology Journal.

[118]  S. Hamid,et al.  Population-attributable estimates for risk factors associated with hepatitis B and C: policy implications for Pakistan and other South Asian countries , 2013, Hepatology International.

[119]  A. Basit,et al.  Prevalence, knowledge and awareness of hepatitis C among residents of three Union Councils in Mansehra. , 2010, Journal of Ayub Medical College, Abbottabad : JAMC.

[120]  S. Chaves,et al.  Surveillance of HCV infection in the Netherlands. , 2003, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[121]  R. Malekzadeh,et al.  Historical epidemiology of hepatitis C virus (HCV) in select countries – volume 3 , 2015, Journal of viral hepatitis.

[122]  M. Lafrenz,et al.  Outcome in a hepatitis C (genotype 1b) single source outbreak in Germany--a 25-year multicenter study. , 2005, Journal of hepatology.

[123]  F. Forastiere,et al.  Mortality of intravenous drug users in Rome: a cohort study. , 1991, American journal of public health.

[124]  M. Grigorescu.  HCV genotype 1 is almost exclusively present in Romanian patients with chronic hepatitis C. , 2009, Journal of gastrointestinal and liver diseases : JGLD.

[125]  E. Essa,et al.  Serum PAI-1 and PAI-1 4G/5G Polymorphism in Hepatitis C Virus-Induced Cirrhosis and Hepatitis C Virus-Induced Hepatocellular Carcinoma Patients. , 2016, Viral immunology.

[126]  A. Schober,et al.  [Epidemiology of chronic hepatitis C in Germany--an analysis of 10,326 patients in hepatitis centres and outpatient units]. , 2008, Zeitschrift fur Gastroenterologie.

[127]  R. Ueda,et al.  Risk Factors and Seroprevalence of Hepatitis B Virus, Hepatitis C Virus, and Human Immunodeficiency Virus Infection in Uzbekistan , 2002, Intervirology.

[128]  D. Harnois,et al.  Aging of Hepatitis C Virus (HCV)-Infected Persons in the United States: A Multiple Cohort Model of HCV Prevalence and Disease Progression , 2010 .

[129]  A. Way,et al.  Egypt Demographic and Health Survey 2000. , 2009 .

[130]  R. Gupta,et al.  Prevalence & risk factors for hepatitis C virus among pregnant women. , 2007, The Indian journal of medical research.

[131]  A. Jeannin,et al.  Trends in drug consumption and risk of transmission of HIV and hepatitis C virus among injecting drug users in Switzerland, 1993-2006. , 2008, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[132]  R. Hotchkiss,et al.  Epidemiology of Bloodstream Infections in a Multicenter Retrospective Cohort of Liver Transplant Recipients , 2015, Transplantation direct.

[133]  D. Vlahov,et al.  Persistence of viremia and the importance of long‐term follow‐up after acute hepatitis C infection , 1999, Hepatology.

[134]  M. Law,et al.  Modelling and calibration of the hepatitis C epidemic in Australia , 2009, Statistical methods in medical research.

[135]  M. Alter,et al.  Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. , 2010, Gastroenterology.

[136]  A. Flaxman,et al.  Global epidemiology of hepatitis C virus infection: New estimates of age‐specific antibody to HCV seroprevalence , 2013, Hepatology.

[137]  D. Garabrant,et al.  Ethnicity, socioeconomic status, transfusions and risk of hepatitis B and hepatitis C infection , 1997, Journal of gastroenterology and hepatology.

[138]  A. Valleron,et al.  Correlation between hepatitis C virus prevalence and hepatocellular carcinoma mortality in Europe , 1999, Journal of viral hepatitis.

[139]  Manfred S. Green,et al.  Risk factors for hepatitis C virus infection among blood donors in Israel: a case‐control study between native Israelis and immigrants from the former Soviet Union , 2007, Transfusion.

[140]  S. Thung,et al.  Acute and chronic hepatitis. , 2006, Seminars in diagnostic pathology.

[141]  R. Jooma,et al.  Prevalence of hepatitis B and C viral infections in Pakistan: findings of a national survey appealing for effective prevention and control measures. , 2010, Eastern Mediterranean health journal = La revue de sante de la Mediterranee orientale = al-Majallah al-sihhiyah li-sharq al-mutawassit.

[142]  Y. Chawla,et al.  Prevalence & significance of hepatitis C virus (HCV) seropositivity in blood donors. , 2006, The Indian journal of medical research.

[143]  B. Kolarić,et al.  Seroprevalence of blood-borne infections and population sizes estimates in a population of injecting drug users in Croatia. , 2010, Central European journal of public health.

[144]  F. Negro,et al.  Applying a system approach to forecast the total hepatitis C virus‐infected population size: model validation using US data , 2011, Liver international : official journal of the International Association for the Study of the Liver.

[145]  P. Easterbrook,et al.  Wide variation in estimates of global prevalence and burden of chronic hepatitis B and C infection cited in published literature , 2016, Journal of viral hepatitis.